DRMA (STOCKS)
Dermata Therapeutics, Inc. Common Stock
$1.450000
-0.240000 (-14.20%)
Prev close: $1.690000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Gerald T. Proehl
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4.82M
- Employees
- 8
- P/E (TTM)
- -0.08
- P/B (TTM)
- 0.36
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-1.65 | $-1.62 | -0.0282 | -1.74% |
|
Jun 2025 (Q2)
|
$-1.66 | $-2.96 | +1.2980 | +43.88% |
|
Mar 2025 (Q1)
|
$-4.50 | $-4.59 | +0.0900 | +1.96% |
|
Dec 2024 (Q4)
|
$-20.60 | $-15.30 | -5.3000 | -34.64% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $9.07M |
| Research and Development | $4.60M |
| Operating Income/Loss | -$9.07M |
| Income/Loss From Continuing Operations After Tax | -$8.85M |
| Income/Loss From Continuing Operations Before Tax | -$8.85M |
| Net Income/Loss | -$8.85M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$8.85M |
| Net Income/Loss Available To Common Stockholders, Basic | -$8.85M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $87.51 |
| Diluted Earnings Per Share | $87.51 |
| Diluted Average Shares | 2,298,373 |
| Assets | $5.07M |
| Current Assets | $5.07M |
| Noncurrent Assets | $0.00 |
| Liabilities | $1.11M |
| Current Liabilities | $1.11M |
| Accounts Payable | $453.43K |
| Wages | $594.14K |
| Other Current Liabilities | $63.74K |
| Noncurrent Liabilities | $0.00 |
| Equity | $3.96M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $3.96M |
| Liabilities And Equity | $5.07M |
| Net Cash Flow From Operating Activities | -$9.28M |
| Net Cash Flow From Operating Activities, Continuing | -$9.28M |
| Net Cash Flow From Investing Activities | $12.58M |
| Net Cash Flow From Investing Activities, Continuing | $12.58M |
| Net Cash Flow From Financing Activities | $7.86M |
| Net Cash Flow From Financing Activities, Continuing | $7.86M |
| Net Cash Flow | -$11.10M |
| Net Cash Flow, Continuing | $2.90M |
| Comprehensive Income/Loss | -$8.85M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$8.85M |
| Other Comprehensive Income/Loss | $0.00 |